{
    "nctId": "NCT01714973",
    "briefTitle": "Study of ST266 Versus Saline in Treating Skin Irritation From Radiation",
    "officialTitle": "Phase I Randomized, Blinded Safety and Efficacy Trial of Amnion-derived Cellular Cytokine Solution (ACCS) Versus Saline Sprayed on the Breast of Women Undergoing Radiation Therapy for Breast Cancer After Surgical Removal of the Tumor",
    "overallStatus": "COMPLETED",
    "conditions": "Radiation-induced Dermatitis",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Adverse Events (AEs) and Significant Adverse Events (SAEs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* A signed IRB - approved Informed Consent;\n* Women 18 - 80 years of age;\n* Biopsy-proven diagnosis of breast cancer with the tumor surgically removed.\n* Whole breast radiation with or without ipsilateral axilla radiation therapy recommended by her radiation oncologist.\n* If a woman is of child-bearing potential, she and her partner must use an effective form of birth control.\n* Willing to participate in the clinical study and comply with the requirements of the trial.\n\nExclusion Criteria:\n\n* Abnormal liver or kidney function studies being greater than 2x the upper limit of normal.\n* Patients on hemodialysis\n* Psychiatric condition or substance abuse which in the Investigator's opinion may pose a threat to patient compliance;\n* History of non-compliance with treatment or clinical visit attendance.\n* Participation in an investigational trial within 30 days of study entry.\n* Women who are pregnant or lactating",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}